Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 1/20 | 0.37 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.37 |
| ▸ | FLT3 | P36888 | 1/20 | 0.35 |
| ▸ | METTL3 | Q86U44 | 10/20 | 0.35 |
| ▸ | METTL14 | Q9HCE5 | 10/20 | 0.35 |
| ▸ | MAOB | P27338 | 2/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | ACACB | O00763 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27247644 | 0.86 | MTNR1A (0.39) | MTNR1AMTNR1BFLT3METTL3METTL14 | |
| SCHEMBL30920754 | 0.85 | MTNR1A (0.37) | MTNR1AMTNR1BFLT3METTL3METTL14 | |
| SCHEMBL27248294 | 0.85 | MAOA (0.40) | MTNR1AMTNR1BFLT3METTL3METTL14 | |
| SCHEMBL27247424 | 0.85 | MAOB (0.49) | MTNR1AMTNR1BFLT3MAOBACHE | |
| SCHEMBL30920852 | 0.84 | MTNR1A (0.37) | MTNR1AMTNR1BFLT3METTL3METTL14 | |
| SCHEMBL30920674 | 0.84 | SMN1; SMN2 (0.35) | MAPK1MEN1KMT2A | |
| SCHEMBL27247192 | 0.84 | MAOB (0.45) | MTNR1AMTNR1BFLT3MAOBACHE | |
| SCHEMBL30946112 | 0.84 | LMNA (0.46) | MAOAMAPK1ACACBMEN1KMT2A | |
| SCHEMBL30920826 | 0.84 | MTNR1A (0.37) | MTNR1AMTNR1BFLT3METTL3METTL14 | |
| SCHEMBL30946137 | 0.83 | MTNR1A (0.37) | MTNR1AMTNR1BFLT3METTL3METTL14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240199546-A1 | INHIBITORS OF SOLUTE CARRIER FAMILY 6A MEMBER 19 (SLC6A19) AND METHODS OF USE THEREOF | HERCULES CAPITAL, INC., AS AGENT | 2024-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199546-A1 | INHIBITORS OF SOLUTE CARRIER FAMILY 6A MEMBER 19 (SLC6A19) AND METHODS OF USE THEREOF | SLC6A19, SLC2A9, SLC6A3 | MTNR1A 158/4885MTNR1B 111/4885FLT3 3961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.